Cystectomy survival outcomes: A single center experience in Australia
Objective: Survival following cystectomy is influenced by gender, age and initial pathology. We report on variation in biopsy versus final surgical pathology and its impact on survival, five year survival of those undergoing cystectomy for bladder urothelial carcinoma, and evaluate any difference between gender and age.
Methods: Patients were selected from our hospital cancer database who underwent a cystectomy for bladder urothelial carcinoma between 1987 and 2015. Patients were considered as having bladder cancer if they had muscle invasive cancer, non-muscle invasive cancer or carcinoma in situ on their final biopsy pathology. Pathology was recorded at last cystoscopy before surgery and based on surgical specimen.
Results: One hundred and twenty-five patients were included, 71% male, and 29% female, with a median age at cystectomy of 67.1 years. Fifty-seven point nine percent of patients had no change between their biopsy and cystectomy histopathology and 18.3% of patients were downgraded, 16.6% of patients were upgraded, and 7.1% had incomplete pathology data. Median survival was 4.6 years and overall five year survival 58.2%. There was no significant difference in survival between genders and no difference when comparing between gender and age > 70 and < 70 years. There was no statistical difference in survival between patients who had their final pathology upgraded, downgraded, or confirmed.
Conclusions: We found lower rates of variation in biopsy versus surgical pathology than reported elsewhere and did not observe a significant association with survival. Our survival outcomes are similar to those within the literature. Gender did not impact on survival, even when comparing between age > 70 and < 70 years.
1. Australian Institute of Health and Welfare. Cancer survival and prevalence in Australia: period estiamtes from 1982 to 2010. Canberra: AIHW; 2012. Contract No.: Cat. no. 65.
2. Scelo G, Brennan P. The epidemiology of bladder and kidney cancer. Nature clinical practice Urology. 2007;4(4):205-17.
3. Tracey E, Roder D, Luke C, Bishop J. Bladder cancer survivals in New South Wales, Australia: why do women have poorer survival than men? BJU Int. 2009;104(4):498-504.
4. Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M. Female with bladder cancer: what and why is there a difference? Translational andrology and urology. 2016;5(5):668-82.
5. Babjuk M, Bohle A, Burger M, Comperat E, Kaasinen E, Palou J, et al. Guidelines of non-muscle invasive bladder cancer (Ta, T1, and CIS). European Association of Urology; 2015.
6. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007;51(1):137-49; discussion 49-51.
7. May M, Brookman-Amissah S, Roigas J, Hartmann A, Storkel S, Kristiansen G, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. European Urology.57(5):850-8.
8. Van Der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol. 2000;164(5):1533-7.
9. Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol. 2003;43(3):241-5.
10. Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102(9 Pt B):1242-6.
11. Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol. 2002;168(3):968-72.
12. Witjes JA, Moonen PM, van der Heijden AG. Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. Urology. 2006;67(4):751-5.
13. Patel HD, Ball MW, Cohen JE, Kates M, Pierorazio PM, Allaf ME. Morbidity of urologic surgical procedures: an analysis of rates, risk factors, and outcomes. Urology. 2015;85(3):552-9.
14. Hounsome LS, Verne J, McGrath JS, Gillatt DA. Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998-2010. European Urology. 2015;67(6):1056-62.
15. Ahmadi N, Delprado WJ, Brooks AJ, Brenner PC, Coombes GM, Grant A, et al. Pathological evaluation and quality of surgery in radical cystectomy in New South Wales, Australia. ANZ J Surg. 2015;85(3):145-9.
16. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010;105(10):1402-12.
17. Margulis V, Lotan Y, Montorsi F, Shariat SF. Predicting survival after radical cystectomy for bladder cancer. BJU Int. 2008;102(1):15-22.
18. Patel MI, Bang A, Gillatt D, Smith DP. Contemporary radical cystectomy outcomes in patients with invasive bladder cancer: a population-based study. BJU Int. 2015.
19. Patel MI, Bang A, Gillett D, Cheluvappa R, Smith DP. Poor survival of females with bladder cancer is limited to those aged 70 years or over: a population-wide linkage study, New South Wales, Australia. Cancer medicine. 2015;4(8):1145-52.
20. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-26.
21. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
22. Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, et al. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol. 2014;66(2):361-70.
23. Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, et al. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. International journal of radiation oncology, biology, physics. 2014;88(5):1048-56.
24. Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011;107(6):898-904.
25. Mitra AP, Skinner EC, Schuckman AK, Quinn DI, Dorff TB, Daneshmand S. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. Urologic oncology. 2014;32(1):52.e1-9.
26. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. The New England journal of medicine. 2002;346(15):1128-37.
27. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. Jama. 1998;280(20):1747-51.
28. Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A. Selective referral to high-volume hospitals: estimating potentially avoidable deaths. Jama. 2000;283(9):1159-66.
29. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Annals of internal medicine. 2002;137(6):511-20.
30. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Annals of surgery. 2007;245(5):777-83.
31. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. The New England journal of medicine. 2011;364(22):2128-37.
32. Roupret M, Yates DR, Varinot J, Phe V, Chartier-Kastler E, Bitker MO, et al. The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. The Canadian journal of urology. 2012;19(5):6459-64.
33. Capogrosso P, Capitanio U, Ventimiglia E, Boeri L, Briganti A, Colombo R, et al. Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality? J Endourol. 2016;30(4):400-5.
34. Shoshany O, Mano R, Margel D, Baniel J, Yossepowitch O. Presence of detrusor muscle in bladder tumor specimens--predictors and effect on outcome as a measure of resection quality. Urologic oncology. 2014;32(1):40.e17-22.